Evidence map›Paper›PMID 41473322›Full record

ArticlebioRxiv : the preprint server for biology2025

Albumin-binding dendrimer-conjugated siRNA enables safe and effective gene silencing throughout the central nervous system.

Hassan H Fakih, Masahiro Ohara, Ashley Summers, Samantha L Sarli, Karen Kelly, Rosemary Gagnon, Bruktawit Maru, Brianna Bramato, Anastasia Khvorova, Jonathan K Watts

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hassan H FakihRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Masahiro OharaRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Ashley SummersRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Samantha L SarliRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Karen KellyRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Rosemary GagnonRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Bruktawit MaruRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Brianna BramatoRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Anastasia KhvorovaRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0001-6928-8071
Jonathan K WattsRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0001-5706-1734

Funding

Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disordersR01NS104022 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANASTASIA KHVOROVA · 2017 to 2026
$6.0M
Next-generation antisense therapeutics for ALS and frontotemporal dementiaR01NS111990 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Robert H Brown, Jonathan K Watts · 2019 to 2026
$5.2M
Chemical engineering of therapeutic RNAs for extrahepatic deliveryR35GM131839 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANASTASIA KHVOROVA · 2019 to 2026
$3.1M
High-throughput Oligonucleotide Production SystemS10OD036329 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KHVOROVA, ANASTASIA · 2024 to 2024
$1.4M
Mid-Scale RNA Synthesis, Purification and Quality Control SystemS10OD020012 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KHVOROVA, ANASTASIA · 2015 to 2015
$563k
NIGMS NIH HHS R35 GM131839NIH HHS S10 OD020012NIH HHS S10 OD036329NINDS NIH HHS R01 NS104022NINDS NIH HHS R01 NS111990
6 · The paper itself

Abstract

Improving siRNA delivery to the central nervous system (CNS) is a major focus for treating the numerous debilitating neurological conditions which have a genetic basis. Here, we present an albumin-binding siRNA based on an amphiphilic dendrimer conjugate (D-siRNA). We demonstrate that D-siRNA achieves effective and homogeneous delivery throughout the CNS following administration into the cerebrospinal fluid (CSF). In mice, a single CSF administration of D-siRNA resulted in potent and durable gene silencing across various brain regions, with effects lasting six months without detectable toxicity. We validate its utility in larger rodents (rats) using intrathecal administration-a clinically relevant route-showing effective and broad delivery and robust silencing. Benchmarking against other clinically relevant siRNA delivery scaffolds revealed that D-siRNA provides comparable delivery and efficacy, with more efficient conversion of gross uptake to functional uptake. These findings support the use of albumin-binding conjugates for brain delivery, and position D-siRNA as a safe, effective, and durable platform for gene silencing in the CNS.

Identifiers

PMID41473322
PMCPMC12746015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.